Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 9NIH 6INDUSTRY 5NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2NET 1

Conditions

Somatostatinoma 5Kidney Neoplasms 5Adrenocortical Carcinoma 5Insulinoma 4Glucagonoma 4Gastrinoma 4Carcinoma, Islet Cell 4Thyroid Neoplasms 3Thyroid Carcinoma, Anaplastic 3Thyroid Cancer, Papillary 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Salivary Gland Neoplasms 3Pheochromocytoma 3Neuroendocrine Tumors 3Head and Neck Neoplasms 3Carcinoma, Medullary 3Adenocarcinoma, Follicular 3Vipoma 2Sarcoma, Synovial 2Sarcoma, Endometrial Stromal 2Pituitary Neoplasms 2Ovarian Neoplasms 2Neurofibrosarcoma 2Neoplasms 2Neoplasm Metastasis 2Malignant mesenchymal tumor 2Liposarcoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2

Interventions

Octreotide 2vatalanib 1motesanib diphosphate 1batifiban 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Vipoma × Endocrine × Clear all
NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Withdrawn
Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡